Kent Imaging Inc. is accelerating its growth through a US$15M investment by TVM Life Science Innovation II SCSp

CALGARY, January 13, 2021 /EIN Presswire/ – Kent Imaging, an innovator in the tissue imaging market, announced today its partnership with TVM Life Science Innovation II SCSp to accelerate the global commercialization of its industry leading SnapshotNIR® product.

SnapshotNIR utilizes near infrared light to determine tissue oxygen saturation (StO2), which is a key indicator of tissue health. Snapshot NIR assesses the microcirculation and conveys a comprehensive picture of tissue health and the healing capacity of wounds or surgical tissue. This FDA cleared, non-invasive approach to tissue assessment brings value to healthcare delivery in various clinical settings including wound care, plastic and reconstructive surgery, and vascular surgery.

“We are enormously proud to partner with TVM, a world-class venture capital fund to enhance Kent’s position as a major player in diagnostic tissue health assessment. The confidence expressed by TVM in Kent’s products and technology reinforces our leadership in bringing innovation to this critical market. With this investment, Kent will expand on its product line, its partnerships and accelerate the introduction of this novel technology globally.” – Pierre Lemire, CEO

“Kent Imaging commercializes innovative oxygenation imaging products targeting limb preservation and reconstructive surgical markets. This is an area with clear unmet need as non-healing wounds are a huge burden with respect to patient outcome and ever rising healthcare costs. TVM’s investment will further establish Kent Imaging on the global stage. We see Kent’s technology as the next major imaging modality and we are excited to be a part of the initiative to bring this technology to the global market. Kent Imaging will benefit from TVM Capital Life Science’s European and North American network to facilitate its market access abroad.” – Dr. Luc Marengere, Managing Partner, TVM Capital Life Science

In addition to the investment, Kent Imaging will also benefit with the addition of Dr. Marengere and Dr. Alexandra MacLean, a Principal with TVM Capital Life Science, to its Board of Directors.

About Kent Imaging Inc.

Kent Imaging, located in Calgary, Alberta, Canada, is a leading innovator in oxygenation imaging, who develops, manufactures and markets medical technology that supports real-time decision making in wound care, vascular and surgical sub-specialties. Kent holds multiple patents in oxygen imaging technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally. For more information about Kent Imaging, visit www.kentimaging.com.

About TVM Capital Life Science

TVM Capital Life Science is providing venture capital to the international pharmaceutical, biopharmaceutical and medical technology industries with more than 35-years of transatlantic investment track record and more than US$2.0B raised. With its advisory, corporate finance and investment teams located in Montreal and Munich, the TVM Capital Life Science team provides investors, as well as entrepreneurs and innovation-seeking biopharmaceutical companies, access to global life science innovation and provides paths for successful tech transfer and commercialization for the benefit of patients and investors alike.

The TVM Capital Life Science team looks back on more than 140 investments and over 100 exits, including more than 45 initial public offerings on all major U.S. and European stock exchanges. The team has gained unrivalled international investment and business development experience with their track record of dedicated board work, significant contribution to global networks in the world of life science research and product development, and a direct knowledge of the local markets. More information: www.tvm-lifescience.com

EIN Presswire release:

https://www.einpresswire.com/article/534419123/kent-imaging-inc-is-accelerating-its-growth-through-a-us-15m-investment-by-tvm-life-science-innovation-ii-scsp?r=pawe3kPQrjTXWz7-WI

Kent Imaging Inc. Receives FDA 510(k) Clearance on SnapshotNIR V3.0

CALGARY, January 6, 2021 /EIN Presswire/ – Kent Imaging announced today the FDA 510(k) clearance for SnapshotNIR V3.0 (KD204) – now available for shipping. This upgrade provides significant feature enhancements to the imaging technology that advances tissue assessment in acute and chronic wounds. The multitude of advancements include the ability to image most skin tones (overcoming the melanin barrier), linear and surface area wound measurements, easy report generation with image comparisons, and enhanced patient file management, to name a few.

SnapshotNIR utilizes near infrared light to determine tissue oxygen saturation (StO2), which is a key indicator of tissue health. Ideal for microcirculation assessment, it conveys a comprehensive picture of the healing capacity of wounds or surgical tissue. This critical information is used to support clinical judgement in choosing, evaluating, and tracking treatment and surgical options throughout the care continuum.

“We are excited to release this enhanced version of SnapshotNIR as part of Kent’s dedication to bringing innovation to this critical market. Robust features asked for by front-line wound care specialists and reconstructive surgeons have been incorporated, delivering a product that can easily track and document wound healing progress and support therapeutic decisions,” noted Pierre Lemire, CEO. “SnapshotNIR V3.0 continues to support the goal of delivering on solutions that aid wound care and surgical specialists in improving patient outcomes and reducing complications.”

About Kent Imaging Inc.

Kent Imaging, located in Calgary, Alberta, Canada, is a leading innovator in oxygenation imaging, who develops, manufactures, and markets medical technology that supports real-time decision making in wound care, vascular and surgical sub-specialties. Kent holds multiple patents in oxygen imaging technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally. For more information about Kent Imaging, visit www.kentimaging.com.

Western Economic Diversification Canada awards Kent Imaging with an investment of $1.75M through the Business Scaleup Program.

Oxygen is the key to life. Kent Imaging provides solutions to instantly measure tissue oxygenation in acute and chronic wounds to help in assessing a wound’s capacity to heal. Kent designs, manufactures and distributes a medical imaging device, SnapshotNIR, from their corporate headquarters in Calgary, AB.

The investment provided through Western Economic Diversification Canada (WD) will be leveraged to expand Kent Imaging’s footprint on a global scale. We are very appreciative of WD, as not only are they providing financial support to industry through these programs, they are also facilitating collaboration between industry and all levels of government to accelerate the growth of the Healthtech Ecosystem in Alberta.

“We are very excited to be a recipient of investment through WD’s Business Scale-up program to assist Kent Imaging in leveraging our innovative imaging technology, SnapshotNIR. Kent’s goal is to provide physicians immediate insight into the ability of tissue to heal, thus improving outcomes and reducing complications during treatment. This investment allows us to accelerate our product innovation and expand our global technology footprint.”

Pierre Lemire, CEO, Kent Imaging

The official release by Western Economic Diversification Canada can be accessed here:

https://www.canada.ca/en/western-economic-diversification/news/2020/12/federal-funding-bolsters-albertas-health-and-life-sciences-sector.html

Tissue Analytics, with their launch of an EHR-Interoperable Marketplace for wound care diagnostic and preventive devices, announces collaborative partnership with Kent Imaging.

This partnership allows physicians to quickly and easily assess tissue viability and track wound healing progression when advanced wound care therapies are applied. Kent’s CEO, Pierre Lemire, is states “An open API from Tissue Analytics provides a key framework where tissue oxygenation images captured with SnapshotNIR can be combined with wound data from other vendors to enhance wound comprehension and impact decision making. This improves the clinically relevant data that is required to assess and manage wounds.” 

Tissue-Analytics-Kent-Imaging-PR

Kent Imaging Inc. and Synchrocare, LLC announce an agreement that provisions Synchrocare, LLC with the distribution of Kent Imaging’s innovative new medical device SnapshotNIR.

SnapshotNIR utilizes near infrared light to assess oxygenated and deoxygenated hemoglobin providing an assessment of tissue oxygenation at all points of care in wounds, limb salvage, vascular, and flap based reconstructive surgery. 

Synchrocare-LLC-announcement-v3

Perry Baromedical and Kent Imaging Inc. announce Strategic Partnership in Hyperbarics

RIVIERA BEACH, Florida, July 17, 2018 (CSN) — Perry Baromedical and Kent Imaging Inc. today announced a Strategic Partnership where Perry will distribute Kent’s Near Infrared Imaging device (SnapshotNIR).

Through this partnership, Perry Baromedical, the only full line manufacturer of hyperbaric chambers in the industry, will continue to extend the innovative solutions that it offers its customers.  Kent’s tissue assessment technology is easy to use, convenient, and provides a cost-effective method of assessing the effects of hyperbaric therapy on wound oxygenation and wound health thus supporting the course of treatment and continuing to build the value Perry brings to its customers.

Oxygenation is widely accepted as the best biomarker of tissue health and healing.  Kent’s device is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports oxygen saturation (StO2), relative oxyhemoglobin level (HbO2), and relative deoxyhemoglobin (Hb) level in superficial tissue. Kent’s NIR multispectral imaging technology displays two-dimensional color-coded images providing critical information to help clinicians determine at risk tissue and guide treatments optimizing patient outcomes in wound care, plastic surgery, and various other reconstructive applications.

“Perry is pleased with our partnership with Kent as it represents the best of multi-spectral imaging technology available.  Our collective commitment to the industry is to offer best of class products with ease of use to our end users and a non-invasive technology for the patients.” Perry President and COO Mary Pat Finn enthusiastically stated.  “The Kent partnership allows Perry to offer essential comprehensive technology to enhance the diagnostic offerings in the wound care and hyperbaric market.”

“This partnership with Perry further optimizes patient treatment and monitoring resulting in better patient outcomes while helping reduce costs to the medical system” said Pierre Lemire, CEO of Kent Imaging.  “We are thrilled to bring together the leading-edge treatment technologies of Perry with the advanced tissue assessment technology of Kent – the winners are the patients, staff, and overall health care system.  This partnership with Perry aligns with Kent’s goal to lower complications and reduce the cost of care in wound healing.”

Features of Kent’s Tissue Oxygenation Assessment device:

  • Cordless handheld portable for use in all care setting
  • Instant tissue assessment
  • Non-invasive with no injectables or dyes
  • A means to track patient progress and treatment effectiveness
  • Provides quantified tissue oxygenation levels
  • No disruption to existing workflow
  • Accurate, unlimited imaging and storage
  • Ease-of-use with minimal training required
  • Low cost device with no disposables or pay per click fees

Kent has received all necessary clearances for product sales in the United States, Canada, and Europe.

About Perry Baromedical

Perry Baromedical Corporation is dedicated to providing the highest quality hyperbaric chambers, EMR software, services and educational programs in the industry. Expertise in advanced engineering technology, software development along with proprietary manufacturing process and global resources, allow us to produce, ship, install, service, and offer education worldwide. Perry Baromedical is the only US hyperbaric chamber manufacturer that builds three acrylic monoplace models, dual place, and multi place units including the largest acrylic monoplace hyperbaric chamber in the world. For more information please visit www.perrybaromedical.com or call 1-800-741-4376.

About Kent Imaging Inc.

Kent Imaging, located in Calgary, Alberta, Canada, is a leading developer of medical technology, who imagines, designs, manufactures and markets imaging technology for wound and surgical care. Kent holds multiple patents in medical technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally. For more information about the company visit www.kentimaging.com.

For further information, please contact:

Perry Baromedical, Sharon Marshall – Corp Communication.

Email: smarshall@perryhbo.com Phone 800.741.4376

Kent Imaging Inc., Jeff Hydar – VP Sales

Email: jhydar@kentimaging.com Phone: 403.455.7610

Kent Imaging Inc. and SerenaGroup announce Strategic Partnership in wound care

CALGARY, Alberta, Canada, June 27, 2018 /CNW/ – Kent Imaging Inc. and SerenaGroup® today announced a Strategic Partnership to jointly improve tissue assessment in wounds with the use of Near Infrared Imaging technology using Kent’s SnapshotNIR device.

Oxygenation is widely accepted as the best biomarker of tissue health and healing.  Kent’s device is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports oxygen saturation (StO2), relative oxyhemoglobin level (HbO2), and relative deoxyhemoglobin (Hb) level in superficial tissue. Kent’s multispectral imaging technology displays two-dimensional color-coded images providing critical information to help clinicians determine at risk tissue and guide treatments to optimize patient outcomes in wound care, plastic surgery, and various other reconstructive applications.

This is a great partnership between one of the leaders in building wound care teams and an innovative tissue assessment technology that is easy to use, convenient, and cost effective. SerenaGroup® will adopt Kent Imaging’s technology as the standard of care for assessing wound oxygenation thus wound health.  Kent will be integrated into each of the SerenaGroup® managed facilities, included in Hyperbaric training courses curriculum, as well as included in future clinical and preclinical research.

“We are pleased to introduce Kent’s imaging system into the wound care protocol at our clinics. One of the most troublesome and elusive criteria in treating wounds is the timely and accurate assessment of viable tissue.” said Dr. Serena MD FACS FACHM MAPWCA, Founder and Medical Director of The SerenaGroup®.  “Kent’s device will propel us a long way down the healing path with a technology that has been lacking across the board in the Wound Care space. ”

“Our joint belief is that we can improve patient care and outcomes by significantly improving clinically relevant data that is required to assess and manage wounds.” added Pierre Lemire, CEO of Kent Imaging.  “We are excited to be partnering with SerenaGroup and with Dr. Serena who has dedicated his career to improving patient outcomes in wound care.”

Features of Kent’s Tissue Oxygenation Assessment device:

  • Cordless handheld portable for use in all care setting
  • Instant tissue assessment
  • Non-invasive with no injectables or dyes
  • A means to track patient progress and treatment effectiveness
  • Provides quantified tissue oxygenation levels
  • No disruption to existing workflow
  • Accurate, unlimited imaging and storage
  • Ease-of-use with minimal training required
  • Low cost device with no disposables or pay per click fees

Kent is available for sale in the United States, Canada, and Europe with FDA Class II clearance, Health Canada clearance, and CE Mark.

About Kent Imaging Inc.
Kent Imaging, located in Calgary, Alberta, Canada, is a leading developer of medical technology, who imagines, designs, manufactures and markets imaging technology for wound and surgical care. Kent holds multiple patents in medical technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally. For more information about the company visit www.kentimaging.com.

About SerenaGroup, Inc.
SerenaGroup® is the leader in wound healing research worldwide. Under the leadership of Dr. Serena, the organization has conducted over 100 clinic trials in collaboration with the nation’s first wound healing cooperative group. SerenaGroup® continues to expand its offerings to include interrelated technology solutions.  SerenaGroup® is a global health care management company with the mission to develop the world’s leading centers of excellence in wound and hyperbaric medicine. SerenaGroup® has placed a special emphasis on clinical performance, outcomes and clinical research in the wound care space. For more information about the company visit www.serenagroups.com

Kent Imaging Inc.: Jeff Hydar – VP Sales, jhydar@kentimaging.com, Phone: 403.455.7610 SerenaGroup®: Anthony Serena – COO, easerena@serenagroups.com, Phone: 617.945.5225

Kent Imaging, Inc. Announces CE Mark for New Multispectral Imaging Product, Kent’s SnapshotNIR

CALGARY, Alberta, Canada, May 30, 2018 (CNW) — Kent Imaging, a leading provider of near infrared imaging solutions, announced today that it has received CE Mark approval for the Kent multispectral Medical Imaging Device (SnapshotNIR).  The Kent device is also listed as a Class II medical device with US FDA and Health Canada.  This now allows Kent to expand its markets with distribution in Europe.

Kent Imaging has been working with European Research partners for the past 6 years to gather and publish clinical results using the Kent Device.

“Translational research is the word of the time.” Said Dr. Flavio Coceani, Scuola Superiore Sant’Anna in Pisa, Italy.  “Kent embodies this hallmark inasmuch as it moves an idea from the bench to the medical practice in a simple, cost-effective format.”

Kent Imaging’s device is the newest advancement in tissue oxygenation and perfusion imaging. The imaging device is handheld, cordless, portable, non-invasive and eliminates the need for tissue contact or injection of dyes. The Kent device operates with similar speed to a point and shoot camera and provides insight into the availability of oxygenated blood in tissue. This enables rapid and improved decision-making throughout the dynamic treatment path and helping to avoid unnecessary complications or corrections across the multiple points of care.

“We are very excited about obtaining CE Mark for our handheld device.”, said Pierre Lemire, CEO of Kent Imaging. “This is another key milestone in Kent’s growth strategy.  We can now engage with our European partners to bring our innovative technology to the European medical community.”

The Kent device has gained acceptance in both flap and implant-based reconstruction, abdominal wall surgery, colorectal surgery, cardiac use, vascular surgery, and various types of wound care. The Kent device is available for use in the operating room, clinics, and other care settings.

About Kent Imaging Inc.

Kent Imaging is an innovative healthcare technology company who imagines, designs, prototypes, commercializes and manufactures spectral imaging solutions for the medical industry. Kent’s products provide low cost non-invasive diagnostic insight into tissue health to aid healthcare personnel to provide the best possible care for patients.  For more information about our company visit us at www.kentimaging.com.

For further information, please contact: Kent Imaging Inc.

Katelyn Oldale – Marketing Manager E-mail: katelyn@kentimaging.com Phone: 1-403.455-7610

Kent Imaging Announces Strategic Partnership to Advance Tissue Assessment

CALGARY, March 20, 2018 –Kent Imaging Inc. announced today a strategic relationship with Allergan Canada to advance tissue assessment in Canada.

This opportunity adds the Kent device to Allegan Canada’s Medical Aesthetics division with another solution for breast augmentation surgery along with AlloDerm®, Natrelle®, Revolve®, and the Keller Funnel®.

The Kent device is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports oxygen saturation (StO2), relative oxyhemoglobin level (HbO2), and relative deoxyhemoglobin (Hb) level in superficial tissue. Kent’s multispectral imaging technology displays two-dimensional colour-coded images providing critical information to help physicians determine at risk tissue and guide treatments to optimize patient outcomes in breast, reconstructive, and various other plastic surgery applications.

“With the Kent device, we can quantify oxygenation which is the best biomarker for tissue health and predictor of tissue viability in creating flaps with surgically reconstructed patients,” said Carmen Enciu, Medical Director and Head of the Canadian Chief Medical Office. This opportunity further reinforces Allergan Canada’s commitment to patients in need of treatment by finding innovative technologies that improve outcomes.”

“We are very excited about this strategic partnership”, said Pierre Lemire, CEO of Kent Imaging. “Working with Allergan Canada, we can help physicians determine the most effective treatment plans which provides them a means of reducing recovery times and patient discomfort, as well as optimizing patient outcomes.”

Features of Kent’s Tissue Oxygenation Assessment device:

  • Cordless handheld portable for use in all care setting
  • Instant tissue assessment
  • Non-invasive with no injectables or dyes
  • A means to track patient progress and treatment effectiveness
  • Provides quantified tissue oxygenation levels
  • No disruption to existing workflow
  • Accurate, unlimited imaging and storage
  • Ease-of-use with minimal training required
  • Low cost device with no disposables or pay per click fees

Kent is now available for sale in both the United States and Canada.

About Kent Imaging Inc.

Kent Imaging, located in Calgary, Alberta, Canada, is a leading developer of medical technology, who designs, manufactures and markets imaging technology for wound and surgical care. Kent holds multiple patents in medical technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally. For more information about our company visit us at www.kentimaging.com.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.

Allergan’s success is powered by our global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan’s website at www.allergan.com

For further information: Media Inquiries: Jeff Hydar, Kent Imaging, jhydar@kentimaging.com, 630.746.2218; Liana Del Medico, Allergan Canada, MR-Canada_Communications@Allergan.com, 905-940-7327

Kent Imaging’s Breakthrough Medical Imaging Device Licensed with Health Canada

CALGARY, Nov. 7, 2017 /CNW/ – Kent Imaging Inc., a leading innovator in multispectral oxygenation imaging, announced today that their handheld SnapshotNIR is a licensed medical device with Health Canada. Kent’s device is also cleared with the U.S. Food and Drug Administration (FDA) and the company is ISO13485 certified.

Kent’s handheld SnapshotNIR measures and displays quantified tissue oxygen saturation levels in superficial tissue. Tissue oxygen saturation measurements provide critical information to help physicians determine at risk tissue and guide treatments to optimize patient outcomes. Kent’s easy to use device is available for sale in the United States and Canada with utility in plastic surgery, colorectal surgery, trauma, wound care, limb salvage, podiatry, burns and cardiac specialties.

“The Kent Imaging camera is unique in its ability to assess oxygenation in tissue using spectroscopy,” said Dr. Earl Campbell MD, FRCSC, practicing surgeon and a member of the Alberta Medical Association and the Canadian Society of Plastic Surgeons. “Plastic surgeons in Calgary, Alberta are already exploring its intra-operative uses when performing breast reconstruction procedures.”

“We are happy to announce our licence with Health Canada,” said Pierre Lemire, CEO of Kent Imaging. “This, along with its FDA clearance, has made our handheld device, the SnapshotNIR, readily available to the physicians and surgeons who require the valuable insight it provides.”

Features of Kent’s SnapshotNIR:

  • Instant and precise visualization of oxygen saturation
  • Non-invasive with no injectable dyes
  • Ability to image the actual wound bed and surrounding tissue
  • Oxygenation measurement of surgical sites or reconstructive flaps
  • A means to track patient progress and treatment effectiveness
  • Ease-of-use with minimal training required
  • Accurate, unlimited imaging
  • Lightweight and completely portable handheld device

About Kent Imaging Inc.
Kent Imaging Inc., a leading innovator in multispectral oxygenation imaging, designs, manufactures, and markets imaging technology to improve health care. The team at Kent Imaging is committed to improving patient outcomes by delivering innovative and practical solutions for the healthcare industry. Kent Imaging holds multiple patents in medical technology and is currently commercializing the breakthrough multispectral imaging solutions that assesses tissue oxygen saturation. The company is headquartered in Calgary, Alberta, Canada, and has locations in Chicago, Los Angeles, Salt Lake City and Seattle.

Kent’s SnapshotNIR is U.S. Food and Drug Administration 510(k) cleared, and Health Canada licensed. The device is available for sale in the United States and Canada. Improving on Kent’s previous KC103, the handheld Kent SnapshotNIR is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports oxygen saturation (StO2), relative oxyhemoglobin level (HbO2), and relative deoxyhemoglobin (Hb) level in superficial tissue. Kent’s multispectral imaging technology displays two-dimensional color-coded images of tissue oxygenation of the scanned surface and reports multispectral tissue oxygenation measurements for selected tissue regions. Tissue oxygen saturation measurements provide critical information to help physicians determine at risk tissue and guide treatments to optimize patient outcomes.